Physician in the Loop: Neurology https://physicianintheloop.org/specialties/neurology/ Transistor (https://transistor.fm) https://feeds.transistor.fm/physician-in-the-loop-neurology The week's innovation news in neurology for neurologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/neurology/. Read by AI voices. Nomad Medical Group, PLLC d74b418a-ada6-5c52-aaf9-4974d4b48d7c yes en Sun, 08 Nov 2026 04:40:49 -0700 Sun, 08 Nov 2026 04:41:14 -0700 https://img.transistorcdn.com/ZJc1kF5q9ceMWu1Q06rKV7ntn7Gtb10c270KWDl3w7w/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kNjFh/N2MxMzllM2YxZjlm/NWVlMDZiYzk0NTMw/MDM3Yy5qcGc.jpg Physician in the Loop: Neurology https://physicianintheloop.org/specialties/neurology/ episodic Nomad Medical The week's innovation news in neurology for neurologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/neurology/. Read by AI voices. The week's innovation news in neurology for neurologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. neurology, neurology news, innovation, medicine, physicians, AI in medicine, weekly briefing Ryan Gillum No No Weekly Briefing for November 1 to 7, 2026 5 5 Weekly Briefing for November 1 to 7, 2026 full b368d99e-6552-4f4f-b01a-a3f17e06c2bf https://share.transistor.fm/s/e3ee01ae Targeting systolic blood pressure under 120 mm Hg after ischemic stroke or transient ischemic attack reduced major cardiovascular events in the 4,368-patient OPTIMAL-STROKE trial, published Nov. 7 in the New England Journal of Medicine.

The Food and Drug Administration accepted uniQure's gene therapy application for Huntington disease for priority review, and Servier said sevasemten failed in a pivotal Becker muscular dystrophy trial.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Targeting systolic blood pressure under 120 mm Hg after ischemic stroke or transient ischemic attack reduced major cardiovascular events in the 4,368-patient OPTIMAL-STROKE trial, published Nov. 7 in the New England Journal of Medicine.

The Food and Drug Administration accepted uniQure's gene therapy application for Huntington disease for priority review, and Servier said sevasemten failed in a pivotal Becker muscular dystrophy trial.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 08 Nov 2026 04:40:49 -0700 Nomad Medical Nomad Medical 170 Lower blood pressure target after stroke cuts cardiovascular events; FDA grants priority review to Huntington gene therapy; sevasemten fails in Becker Lower blood pressure target after stroke cuts cardiovascular events; FDA grants priority review to Huntington gene therapy; sevasemten fails in Becker Neurology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 25 to 31, 2026 4 4 Weekly Briefing for October 25 to 31, 2026 full 663fbb9a-7dc8-438f-b5f0-737d6d25da1c https://share.transistor.fm/s/6e7f5838 Acumen Pharmaceuticals said Oct. 30 that its oligomer-targeting antibody sabirnetug missed its primary end point in the phase 2 ALTITUDE-AD trial in early Alzheimer disease and that it will stop developing the drug. In JAMA Neurology, a self-guided internet program reduced functional seizure frequency versus standard care.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Acumen Pharmaceuticals said Oct. 30 that its oligomer-targeting antibody sabirnetug missed its primary end point in the phase 2 ALTITUDE-AD trial in early Alzheimer disease and that it will stop developing the drug. In JAMA Neurology, a self-guided internet program reduced functional seizure frequency versus standard care.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 01 Nov 2026 04:11:30 -0700 Nomad Medical Nomad Medical 130 Sabirnetug misses primary end point in phase 2 Alzheimer trial; self-guided online program cuts functional seizures in randomized trial Sabirnetug misses primary end point in phase 2 Alzheimer trial; self-guided online program cuts functional seizures in randomized trial Neurology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 11 to 17, 2026 3 3 Weekly Briefing for October 11 to 17, 2026 full 4fb759c4-a116-47ee-806c-b7f4bfbd7de4 https://share.transistor.fm/s/e48fd638 University of Pennsylvania researchers described in Nature Medicine a large language model platform that links EEG monitoring to a smartphone app and converses with people with epilepsy. Other studies tested expert review of AI-flagged long-term EEG and tracked harmful ideation or behavior after thalamic deep brain stimulation for epilepsy, and a pivotal trial implanted its first U.S. patient with an ultra-thin migraine neuromodulation device.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> University of Pennsylvania researchers described in Nature Medicine a large language model platform that links EEG monitoring to a smartphone app and converses with people with epilepsy. Other studies tested expert review of AI-flagged long-term EEG and tracked harmful ideation or behavior after thalamic deep brain stimulation for epilepsy, and a pivotal trial implanted its first U.S. patient with an ultra-thin migraine neuromodulation device.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 18 Oct 2026 03:56:46 -0600 Nomad Medical Nomad Medical 229 Language model platform talks with epilepsy patients during EEG monitoring; AI-assisted EEG review cuts reading time; thalamic DBS harms tracked Language model platform talks with epilepsy patients during EEG monitoring; AI-assisted EEG review cuts reading time; thalamic DBS harms tracked Neurology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 5 to 11, 2026 2 2 Weekly Briefing for October 5 to 11, 2026 full 85729070-1ae8-4eed-ae1b-bc3cd3274696 https://share.transistor.fm/s/bc8ee1d8 The Food and Drug Administration (FDA) accepted XCath's Iris system, a robot intended for remote thrombectomy in acute ischemic stroke, into its Total Product Life Cycle Advisory Program pilot, the company said. Separately, Inbrain Neuroelectronics and the MINIGRAPH consortium reported a robotic method for implanting ultra-thin graphene brain-computer interfaces, validated in a large animal model.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-10-05/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> The Food and Drug Administration (FDA) accepted XCath's Iris system, a robot intended for remote thrombectomy in acute ischemic stroke, into its Total Product Life Cycle Advisory Program pilot, the company said. Separately, Inbrain Neuroelectronics and the MINIGRAPH consortium reported a robotic method for implanting ultra-thin graphene brain-computer interfaces, validated in a large animal model.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-10-05/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Mon, 12 Oct 2026 03:52:10 -0600 Nomad Medical Nomad Medical 135 FDA takes XCath's remote stroke thrombectomy robot into TAP pilot; consortium develops robotic implantation for graphene brain implants FDA takes XCath's remote stroke thrombectomy robot into TAP pilot; consortium develops robotic implantation for graphene brain implants Neurology,physicians,medical news,weekly briefing No Weekly Briefing for September 28 to October 4, 2026 1 1 Weekly Briefing for September 28 to October 4, 2026 full 336ee9db-a9fb-4cb9-b778-ed2ed8712a30 https://share.transistor.fm/s/324d9f8b Genentech said Sept. 29 that the Food and Drug Administration (FDA) accepted its application for fenebrutinib in relapsing and primary progressive multiple sclerosis (MS) under priority review. In JAMA Neurology, the CHOICE trial found that hearing aids did not significantly reduce conversion from mild cognitive impairment (MCI) to dementia-level impairment.

Congress sent the ACT for ALS reauthorization to the president, and a phase 3 trial in Niemann-Pick disease type C missed its primary end point.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Genentech said Sept. 29 that the Food and Drug Administration (FDA) accepted its application for fenebrutinib in relapsing and primary progressive multiple sclerosis (MS) under priority review. In JAMA Neurology, the CHOICE trial found that hearing aids did not significantly reduce conversion from mild cognitive impairment (MCI) to dementia-level impairment.

Congress sent the ACT for ALS reauthorization to the president, and a phase 3 trial in Niemann-Pick disease type C missed its primary end point.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Mon, 05 Oct 2026 21:35:11 -0600 Nomad Medical Nomad Medical 215 FDA accepts fenebrutinib filing for relapsing and primary progressive MS; hearing aids miss CHOICE end point; Congress passes ACT for ALS renewal FDA accepts fenebrutinib filing for relapsing and primary progressive MS; hearing aids miss CHOICE end point; Congress passes ACT for ALS renewal Neurology,physicians,medical news,weekly briefing No